Ignite Creation Date:
2025-12-24 @ 6:50 PM
Ignite Modification Date:
2025-12-27 @ 1:01 PM
Study NCT ID:
NCT01142557
Status:
COMPLETED
Last Update Posted:
2014-07-11
First Post:
2010-06-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis
Sponsor:
Merck KGaA, Darmstadt, Germany
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2004-06
Start Date Type:
None
Primary Completion Date:
2005-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2005-11
Completion Date Type:
ACTUAL
First Submit Date:
2010-06-10
First Submit QC Date:
None
Study First Post Date:
2010-06-11
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2014-07-09
Last Update Post Date:
2014-07-11
Last Update Post Date Type:
ESTIMATED